MedTrace Logo

Neutrophil Gelatinase-associated Lipocalin Concentration in Coronary Artery Disease

NCT00749281 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2010-07-08

No results posted yet for this study

Summary

Serum NGAL has been described as a biomarker of neutrophil activation and an inflammatory marker which correlates to obesity and its metabolic complications. Since neutrophil activation has been implicated in the pathogenesis of coronary artery disease, the investigators hypothesized that serum NGAL levels would be higher in patients with CAD and that serum concentration would correlate with the extent of CAD as documented by coronary angiography, serving as a potential biomarker of the severity of CAD.

Conditions

Sponsors & Collaborators

  • Cardiovascular Research Society, Greece

    lead OTHER

Principal Investigators

  • Demosthenes Katritsis, MD,PhD · Athens Euroclinic and Cardiovascular Research Society

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-03-31
Completion
2009-09-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00749281 on ClinicalTrials.gov